✦ LIBER ✦

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab

✍ Scribed by Jolien Tol; Jeroen R. Dijkstra; Marjolein Klomp; Steven Teerenstra; Martin Dommerholt; M. Elisa Vink-Börger; Patricia H. van Cleef; J. Han van Krieken; Cornelis J.A. Punt; Iris D. Nagtegaal

Book ID: 116430383
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 559 KB
Volume: 46
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2010.03.036

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Magnetic Resonance Imaging as an Early I

Magnetic Resonance Imaging as an Early Indicator of Clinical Outcome in Patients With Metastatic Colorectal Carcinoma Treated With Cetuximab or Panitumumab

✍ Ricotta, Riccardo; Vanzulli, Angelo; Moroni, Mauro; Colnago, Barbara; Oriani, Ma 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 419 KB

Clinical Usefulness of EGFR Gene Copy Nu

Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study

✍ Personeni, N.; Fieuws, S.; Piessevaux, H.; De Hertogh, G.; De Schutter, J.; Bies 📂 Article 📅 2008 🏛 American Association for Cancer Research 🌐 English ⚖ 276 KB

Clinical predictors of severe toxicity i

Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer

✍ Roberto Díaz; Jorge Aparicio; Jorge Molina; Laura Palomar; Alejandra Giménez; Jo 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 334 KB

Detection of KRAS Oncogene in Peripheral

Detection of KRAS Oncogene in Peripheral Blood as a Predictor of the Response to Cetuximab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer

✍ Yen, L.-C.; Yeh, Y.-S.; Chen, C.-W.; Wang, H.-M.; Tsai, H.-L.; Lu, C.-Y.; Chang, 📂 Article 📅 2009 🏛 American Association for Cancer Research 🌐 English ⚖ 202 KB

471 KRAS, BRAF and PIK3Ca Mutations as P

471 KRAS, BRAF and PIK3Ca Mutations as Predictors of Outcome From Maintenance Therapy with Bevacizumab with or Without Erlotinib After First Line Combination Therapy for Metastatic Colorectal Cancer: Results of the Phase III ACT Trial NCT00598156 Translational Study

✍ Spindler, K.G.; dePont Christensen, R.; Andersen, R.F.; Pallisgaard, N.; Johnson 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 59 KB